Zoldonrasib plus chemotherapy for metastatic pancreatic cancer with KRAS mutation
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests whether adding a new drug called zoldonrasib to standard chemotherapy works better than chemotherapy alone for pancreatic cancer that has spread and has a specific KRAS G12D mutation. The goal is to see if this combination helps patients live longer and control their cancer better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older and able to give informed consent
- Pancreatic cancer that has spread to other parts of the body, diagnosed within the last 6 weeks
- Your cancer must have the specific KRAS G12D genetic mutation
- Good overall health and ability to perform daily activities (no more than minimal limitations)
- No prior chemotherapy or cancer drugs for advanced pancreatic cancer
- Able to swallow and take oral medications, with organs (liver, kidneys, bone marrow) functioning adequately
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two new targeted pills (zoldonrasib and daraxonrasib) compared to the standard chemotherapy (gemcitabine and nab-paclitaxel) as the first treatment for metastatic pancreatic cancer with a specific KRAS G12D mutation. The new pills may specifically attack cancer cells with this mutation.
This trial tests a new targeted therapy (daraxonrasib) combined with standard chemotherapy as the first treatment for people whose pancreatic cancer has spread. The goal is to see if this combination can help shrink or control the cancer better than chemotherapy alone.
This trial tests a new medicine (DN022150) combined with standard chemotherapy as a first treatment for advanced pancreatic cancer that has a specific genetic change called KRAS G12D. The combination may help shrink or slow the cancer better than chemotherapy alone.
This study tests a new targeted drug called sotorasib combined with standard chemotherapy for people with advanced pancreatic cancer that has a specific KRAS G12C mutation. The goal is to see if the combination works better than chemotherapy alone.
This trial tests an experimental drug (SNV1521) combined with a RAS inhibitor for people with advanced pancreatic cancer. The goal is to see if this combination is safe and can help shrink or control the cancer.
This trial tests a new experimental drug, RNK08954, for people with advanced pancreatic cancer that has a specific genetic change called KRAS G12D. The goal is to see if the drug is safe and can help shrink or slow the cancer.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.